Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 27, 2026eJHaemOpen Access

Efficacy and Safety of Daratumumab‐Based Regimens in Multiple Myeloma: A Systematic Review and Meta‐Analysis of Phase III Randomized Controlled Trials

View Full Paper
Ask AI
Bookmark
Share

Authors

AKA KhanHAHafsa AjmalMKM Mohamed Khalid

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates daratumumab regimens improving PFS in multiple myeloma, highlighting safety concerns.

Key Points

  • This analysis aims to assess the efficacy and safety of daratumumab-based regimens in treating multiple myeloma.
  • Systematic search of PubMed, Scopus, Cochrane CENTRAL, and Google Scholar from January 2015 to December 2024.
  • Included nine Phase III randomized controlled trials with a total of 4556 participants and a mean follow-up of 44.3 months.
  • Quality and outcomes were assessed using the Cochrane RoB 2.0 tool and RevMan 5.4.
  • Daratumumab-based regimens improved progression-free survival (HR 0.55, 95% CI 0.46–0.66).
  • No significant overall survival advantage was observed (RR 0.90, p = 0.25).
  • Increased risks of pneumonia (RR 1.74, p < 0.0001), secondary malignancies (RR 1.46, p = 0.003), neutropenia (RR 1.25, p = 0.006), and thrombocytopenia (RR 1.17, p = 0.01).

Cite This Study

Khan et al. (2026) studied this question.

synapsesocial.com/papers/6a6700a340bca442e0d4a806https://doi.org/10.1002/jha2.70362
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical Outcomes of Daratumumab-Containing Regimens in Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials2026
  2. 2Daratumumab in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials2025 · 2 citations
  3. 3Meta-analysis of the prognostic efficacy of daratumumab combined with standard therapy in high-risk multiple myeloma2025
  4. 4Impact of Daratumumab in Transplant Eligible/Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Meta-Analysis of Phase- III Trials2024
  5. 5Daratumumab in the frontline management of newly diagnosed multiple myeloma: An overview of systematic reviews and meta-analyses.2026